OrganX is a Non-Profit Health Organization (NPHO) established to accelerate disruptive advances in translational biomedical research and clinical practice through the development of cutting-edge digital health technologies.
OrganX is incorporated in Switzerland under Art. 60 ff ZGB
We were initially created to foster the digitalization of the transplantation care continuum and establish / govern the first global AI-driven Blockchain-powered solid organs exchange and tokenized ecosystem in the world for 190+ countries.
The advanced technological capabilities we have developed for transplantation attracted many requests for research partnerships to apply this expertise outside of transplantation.
This led us to rapidly broaden our scope to Non Communicable Diseases leveraging our expertise in Digital Health, AI, Blockchain and Gene Expression to accelerate the use and adoption of Medical AI in oncology, cardiometabolic, inflammatory and rare diseases.
Our vision is to change the practice of medicine by augmenting members of the healthcare community and patients to help them make the most impactful clinical decisions through the use of highly innovative predictive and preventive outcomes-based digital technologies
Our goals goals directly align with WHO Digital Health's objectives. WHO believes that the use and scale up of digital health solutions can revolutionize how people worldwide achieve higher standards of health, and access services to promote and protect their health and well-being.
Digital health provides opportunities to accelerate progress in healthcare related Sustainable Development Goals (especially SDG 3) and achieving the triple billion targets -improve the health of 3 billions people by 2023- as articulated in United Nations WHO's Thirteenth General Program of Work
We established the first Blockchain Organs Exchange in the World supported by clinical institutions
At a time of global organs scarcity, this concept is going to revolutionize solid organs transplantation worldwide, combining Blockchain with AI
The exchange is operated on a nonprofit basis and aligns the incentives of all stakeholders along the transplantation continuum by making its processes more effective, efficient, transparent, secured and trustworthy - Creating a fully virtualized and tokenized transplant ecosystem with trust at its core
We leverage advanced AI combined with transcriptomics and gene expression capabilities to enhance current clinical practice
These minimally invasive AI-piloted diagnostics are improving disease monitoring, clinical decision, and patients’ outcome
For example, our world class Cell-Free DNA AI Platform (cfDNA-AI) allows us to develop solutions in the field of Transplantation, Oncology, Cardiology or Inflammation
This platform therefore increases the ability to detect allograft injuries, multiple cancer types, autoimmune diseases or disease progression much earlier and more accurately than the standard of care through AI augmentation of recent biological and molecular testing technologies
We provide assistance to world-leading private and public institutions to optimize the design, operationalization and outcomes of their clinical trials in the field of NCDs
We leverage our unique access to highly qualified and vetted translational and longitudinal healthcare databases to develop and train our advanced medical AI algorithms
This allows us to identify and segment patients, identify and validate potential drug candidates and biological targets with unprecedented accuracy and speed, reducing CAPEX, increasing ROI and mitigating risks
Our Public-Private-Partnership platform allows us to support countries in the developing world with under-invested healthcare ecosystems - particularly Africa
We partner with Healthcare Authorities (HAs) and healthcare institutions (HCOs) to set-up local or pan-countries biomedical research institutions and develop research capabilities of local Healthcare professionals (HCPs)
A small proportion of research activities are performed out of developing counties and we ought to change this. Also, a lot of diseases prevalent in these countries are not well understood, diagnosed and treated, and would benefit from advanced digital technologies to further their understanding - especially the growing burden of NCDs
We have developed a platform which allows us to design clinically-relevant algorithms and convert them into regulated medical device which can be integrated into the care continuum
These software can be used to support clinical decision making for diagnosis, prognosis or patient monitoring across the disease continuum. They can be enhanced with IoT based solutions for real-time real-world-evidence collection and analysis
They all demonstrate significant clinical utility, substantial value savings for the healhcare ecosystem and advancements to the practice of medicine
The virtual platforms and regulated digital medical devices we develop with our partners lead to substantial improvements in quality of life and life expectancy of patients affected by severe NCDs versus current standard of care
Copyright © 2020 OrganX - All Rights Reserved
Medical AI Powered